Gilead Sciences (GILD) Stock Rating Upgraded by BidaskClub

Gilead Sciences (NASDAQ:GILD) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other brokerages have also issued reports on GILD. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price on the stock. in a research report on Monday, September 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $85.11.

Gilead Sciences (GILD) opened at $75.57 on Thursday. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27. The stock has a market capitalization of $97,108.04, a PE ratio of 7.76, a P/E/G ratio of -1.25 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the company posted $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. equities analysts predict that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.

In other news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock worth $37,404,139 in the last quarter. 1.30% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Keel Point LLC increased its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares during the last quarter. Paradigm Financial Advisors LLC increased its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the last quarter. West Oak Capital LLC increased its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the last quarter. First Heartland Consultants Inc. increased its holdings in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC increased its holdings in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 76.23% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences (GILD) Stock Rating Upgraded by BidaskClub” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2017/12/16/gilead-sciences-gild-stock-rating-upgraded-by-bidaskclub.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply